Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145766 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety of a Purified Vero Rabies Vaccine
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT03145766 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 320 participants.
The verdict
NCT03145766, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
This multicenter, observer-blind, controlled, randomized, Phase II study was designed to evaluate different formulations of the Purified Vero Rabies Cell vaccine VRVg.
Interventions
- BIOLOGICAL VRVg 2
- BIOLOGICAL VRVg 1
- BIOLOGICAL Imovax Rabies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03145766
The ClinicalTrials.gov registry entry for NCT03145766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which VRVg 2 is the first listed.
NCT03145766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03145766 about?
NCT03145766 is a clinical study titled "Immunogenicity and Safety of a Purified Vero Rabies Vaccine". This multicenter, observer-blind, controlled, randomized, Phase II study was designed to evaluate different formulations of the Purified Vero Rabies Cell vaccine VRVg.
What is the current status of trial NCT03145766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2017-04-17. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT03145766?
The interventions under investigation include: VRVg 2 (BIOLOGICAL), VRVg 1 (BIOLOGICAL), Imovax Rabies (BIOLOGICAL).
Who is sponsoring clinical trial NCT03145766?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.